Iodine

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Iodine
   1. Pharmacist Assessment Report
   2. Iodine: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Iodine: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Iodine, so there is currently no new predicted indication. The recorded uses of this drug are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	0
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
285B	nan	nan	Valid

Safety Considerations

• Drug Interactions (all moderate severity): Iodide I-131, Iodide I-123 and lithium carbonate.
• Knowledge-graph contraindication signals (from the TxGNN knowledge graph, not product label text): thyroid conditions (hypothyroidism, myxedema, congenital hypothyroidism, Hashimoto thyroiditis), kidney disease, liver disease, gallbladder disease, epilepsy, blood disorders (thrombocytopenia, neutropenia, agranulocytosis), respiratory conditions (bronchitis, respiratory failure, pulmonary tuberculosis), cardiac conduction disorders (atrioventricular block, atrioventricular dissociation, heart block), pyoureter, and hypocomplementemic urticarial vasculitis.
• Safety signals in the literature: radioiodine-related salivary and lacrimal gland dysfunction, fetal thyroid hyperplasia after iodinated contrast, and acne exacerbation with systemic iodine.

Please refer to the TGA-approved Product Information (PI) for label warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---